Nanjing, China

Zhengjun Wang

This inventor holds 1 USPTO granted patent. Top assignee: Jiangsu Medolution Ltd. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhengjun Wang. Retrieved from https://idiyas.com/inventor/zhengjun-wang-y7yfzh1w

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zhengjun Wang and Pharmaceutical Formulation Innovation.

Introduction

Zhengjun Wang is an inventor based in Nanjing, China, associated with Jiangsu Medolution Ltd. His patent work includes a pharmaceutical composition and preparation method involving a substituted crotonamide compound.

Latest Patents

Wang is credited with 1 patent, titled “Substituted crotonamide pharmaceutical composition and preparation method therefor.” The invention describes a composition containing 5–50 parts of (E)-N-(3-cyano-7-ethoxy-4-(3-ethynylphenylamino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate, alongside specified quantities of filler, disintegrant, adhesive, and lubricant. The filler is selected from carbohydrates. The patent also describes a method for preparing the composition.

Career Highlights

Wang’s listed patent reflects work on pharmaceutical formulation, including the combination of an active compound with excipients and a preparation method. He is associated with Jiangsu Medolution Ltd.

Collaborations

Wang’s listed coworkers include Haitao Tang and Bei Wang.

Conclusion

Zhengjun Wang’s patent activity centers on a substituted crotonamide pharmaceutical composition and its preparation, highlighting his contribution to pharmaceutical formulation innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…